Commentary on Pharmacometrics for Immunotherapy.

about

Commentary on Pharmacometrics for Immunotherapy.

Item

http://www.wikidata.org/entity/Q39082975

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Commentary on Pharmacometrics for Immunotherapy.

@en

Commentary on Pharmacometrics for Immunotherapy.

@nl

type

Item

label

Commentary on Pharmacometrics for Immunotherapy.

@en

Commentary on Pharmacometrics for Immunotherapy.

@nl

prefLabel

Commentary on Pharmacometrics for Immunotherapy.

@en

Commentary on Pharmacometrics for Immunotherapy.

@nl

P1476

Commentary on Pharmacometrics for Immunotherapy.

@en

P2093

P Berraondo

http://www.w3.org/2001/XMLSchema#string

P2860

Immune checkpoint blockade: a common denominator approach to cancer therapy

Oncology meets immunology: the cancer-immunity cycle.

PD-1/PD-L1 inhibitors.

Quantitative Characterization of the Exposure-Response Relationship for Cancer Immunotherapy: A Case Study of Nivolumab in Patients With Advanced Melanoma.

Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors.

Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab.

Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma.

Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors.

Using Model-Based "Learn and Confirm" to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial.

Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma.

P304

8-10

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PSP4.12162

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

María J. Garrido

Iñaki F. Trocóniz

Pedro Berraondo

P577

2016-12-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27997736

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

P932

5270298

http://www.w3.org/2001/XMLSchema#string